D3 Bio, a Chinese drug developer that studies and specifically targets areas where existing approaches to care are not delivering satisfactory outcomes, has raised $200 million in Series A funding.
The round featured Boyu Capital, Matrix Partners China, Sequoia Capital China, Temasek Holdings, and the corporate venture fund of local pharmaceutical services outsourcing player WuXi AppTec. According...
Yunwang Wandian, the e-commerce services arm of Suning.com, one of China’s largest retailers, has raised a RMB6 billion ($912 million) Series A round led by Shenzhen Capital Group.
Southeast Asia-focused private equity firm KV Asia Capital has exited TF Value Mart (TFVM), a Malaysia-based grocery retailer in which it has held a controlling stake since 2016, to Intermediate Capital Group (ICG).
NextGen Funds Management, a newly established GP in Australia, has launched what it is calling the country’s first dedicated artificial intelligence (AI) fund.
Hong Kong’s 3W Fund Management has led a $43 million Series E round for CANbridge Pharmaceuticals, a Beijing-based drug developer that focuses cancer and rare diseases.